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A randomized controlled trial to
evaluate utilization of physical activity
recommendations among patients of
cardiovascular healthcare centres in Eastern
Slovakia: study design and rationale of the
AWATAR study
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Sijmen A. Reijneveld2,6 and Jitse P. van Dijk2,4,6
Abstract
Background: Guidelines on modifiable risk factors regarding cardiological patients are poorly implemented in
clinical practice perhaps due to low health literacy. Several digital tools for improving lifestyle and behavioural
intervention were developed. Our primary aim is to evaluate the effectiveness of a digital exercise prescription tool
on the adherence to physical activity recommendations among patients with cardiovascular diseases.
Methods: A randomized controlled trial will be realized in cooperation with Cardiovascular Health Centres in
Eastern Slovakia. Patients recruited through their cardiologists, will be randomised at 1:1 ratio to the three-months’
experimental condition or control condition. The experimental group will receive standard lifestyle consultation
leading to individually optimized prescription of physical activity. The control group will receive standard, usual-
cardio-care lifestyle counselling, also in the domain of physical activity. The digital system will be used for
optimized exercise prescription. The primary outcome is a change in the patient’s adherence to exercise
recommendations. Data will be collected in both groups prior to consultation and after 3 months.
Discussion: This study protocol presents background and design of a randomized control trial to investigate the
effectiveness of a digital system-provide exercise prescription tool on the adherence to physical activity
recommendations. An optimized exercise prescription that better reflects patient’s diagnosis, comorbidities and
medication can have a significant impact on secondary prevention of cardiovascular disease. This trial can provide
important evidence about the effectiveness of digital exercise guidance in everyday practice of cardiovascular
healthcare.
Trial registration: The study was registered on 1st November, 2017 and is available online at ClinicalTrials.gov
(ID:NCT03329053).
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Background
The age-standardised prevalence rate of cardiovascular
disease (CVD) among the Slovakian male population
(9,403 per 100,000) is the highest within the EU coun-
tries, while among females the comparable prevalence
rate, approaching 7000 per 100,000, is the second high-
est across the EU member states [1]. In response to
these statistics, a number of action calls are nowadays
proclaimed for better and more effective prevention of
CVD [2–6]. Exercise prescription is an essential part of
primary and secondary CVD prevention programs.
Increasing exercise is clinically efficient in blood pres-
sure management. A systematic review and meta-
analysis of randomized controlled trials focused on the
effects of exercise intervention in normotensive and
hypertensive patients confirmed that resistance [7] and
endurance [8] training lowers the systolic and diastolic
blood pressure in patients with CVD. Exercise-induced
hypertension reducing effects were confirmed in young
[9], middle-aged [10] and elderly [11–13] population and
also in patients with low responsiveness to hypertension
medical treatment [14, 15]. Physical activity (PA) is seen
as an effective modulator of the endothelial function
[16], which was recognized as a main trigger of the
cardioprotective effects of exercise [17–20]. Regular ex-
ercise performed by middle-aged and older healthy men
should prevent age-associated loss in endothelium-
dependent vasodilation and restore endothelial activity
to levels similar to those of younger men [21]. Moreover,
PA was able to attenuate the deleterious effect of nitric
oxide synthase gene polymorphism on the systolic blood
pressure [22] and has shown to have positive impacts on
glycaemic control [23], cholesterol profile [24] and lipo-
protein subclass profile [25].
To ensure maximal effectiveness and safety of exer-
cise interventions [26, 27], experts in the field of car-
diovascular health are regularly updating the
guidelines containing recommendations for PA of pa-
tients with CVD. Between 2004 and 2006, the Euro-
pean Society of Cardiology (ESC) published miniseries
of position papers that summarized specific recom-
mendations for PA of patients by pathology [28–33]. A
three-part miniseries published by the ESC in 2012
was describing the importance of PA and exercise mo-
dalities in the management of cardiovascular health.
This time, exercise recommendations were dedicated
for the general population [34], individuals with car-
diovascular risk factors [35], and individuals with CVD
[36]. The latest upgrade of ESC’s guidelines for PA was
done in the year 2016 [37].
Despite the strong emphasis on regular exercise
during lifestyle counselling [38], in the EUROASPIRE
IV (European Society of Cardiology survey on the
lifestyle, risk factor and therapeutic management of
coronary patients), more than 59% of the interviewed
patients reported little or no PA [39]. To clarify these
conflicting observations, we need take to account the
ecological factors [40], the quality of communication
between care-providers and patients, [41, 42] and the pa-
tient’s skills to access, understand and use of disease-
specific instructions and recommendations [43, 44]. The
latter domain is also labelled as the patient’s health
literacy (HL). The HL level influences the patient’s
use of healthcare, quality of disease management and
health risk behaviours [45] and reflects patient’s pro-
activity in attempting to utilize health literacy skills [43].
Sufficient HL is significantly associated with improved
health outcomes with a lower cost of care [45], while
HL inadequacies can compromise patient safety, worsen
management of a disease and increase the incidence of
health conditions requiring intense medical assistance or
hospitalization [46]. In older adults, inadequate HL was
significantly associated with poor implementation of PA
recommendations [47]. For improvement of patient’s ac-
cessibility and applicability of health-related knowledge in
real life, we need to emerge that patients and health pro-
fessionals cannot address these needs independently [48].
For cardio-clinicians nowadays, the available time is very
limited to implement all parts of the long versions of dis-
ease-, comorbidity-, and medication-specific guidelines for
prevention of CVD [28–37]. Behavioural interventions me-
diated by a digital tool may be a feasible route to improve
cardiovascular-related medication adherence and clinical
outcomes [49–51]. For the improvement of exercise pre-
scriptions accessibility and applicability in the secondary
prevention of CVD, a digital support system for optimized
exercise prescription seems to be appropriate. In response
to this request, the European Association of Preventive
Cardiology developed and introduced the Exercise Prescrip-
tion in Everyday Practice and Rehabilitative Training
(EXPERT) tool [52]. In this “utilization of physical activity
recommendations among patients of cardiovascular health-
care centres” (AWATAR) trial, we will assess whether the
EXPERT tool can effectively increase the utilization of
exercise recommendations among patients with CVD. The
effects of such a digital intervention may further be moder-
ated by HL. Therefore, we will try to confirm that patients
with higher HL might benefit more from the digital tool
prescription compared with patients with lower HL.
The aims of the AWATAR trial are therefore
(1) to determine and compare the utilization of
exercise recommendations after exercise
prescription according to digital training and
decision support system as compared to exercise
prescription following the standard informative
procedure among patients with CVD.
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(2) to determine whether HL moderates the effect of
exercise prescription according to the digital
training and decision support system on the indices




To ensure complete reporting and sufficient replicability
of our trial, we describe its design following the SPIRIT
2013 Statement [53] and create a schedule of enrolment,
interventions, and assessments planned on the trial
based on the SPIRIT template (Table 1). The AWATAR
study will be the first randomized controlled trial (RCT)
in which the utilization of exercise recommendations
between the standard lifestyle informative procedure and
the digital training and decision system informative pro-
cedure will be compared. Based on the reviewed litera-
ture, we hypothesize that a higher rate of adherence
between the patient’s 3 months exercise report and
patient’s digital tool exercise prescription will be ob-
served in the experimental group compared with a
three-months waiting group that receives care-as-
usual. The trial protocol was approved by Human
Research Ethics Committee of the Pavol Jozef Safarik
University (approval no. PJSU-V-0825/17–1).
Participants
All potentially eligible participants from the cooperat-
ing Cardiovascular Health Centres (CHCs) will be
screened and selected according the inclusion criteria
exclusively through their cardiologists and receive
written information about the trial. Within a week
they will be contacted by phone to be provided by
additional details about the trial and to confirm their
availability to participate in the study. After tele-
phonic agreement to participate in the study, they will
be invited to an introductory session with the treating
cardiologist. The cardiologist will review the inclusion
criteria as indicated above and the exclusion criteria
and discuss with the patient further study details. At
a final formal step, a written informed consent form
will be obtained from the participants. Following the
introductory session, the baseline assessments of par-
ticipants will be made.
Sample size
The trial has been designed to detect an effect size of 0.
33 for the intervention under study compared to care-
as-casual, regarding the primary outcome of agreement
between patient’s reported and prescribed exercise indi-
ces (type, duration, intensity and frequency - variables
summarized in Table 4), with a power of 80% at an α
level of 0.05 (two-tailed). An effect size of 0.60 has previ-
ously been shown to be realistic [50] and has sufficient
clinical relevance. This requires 150 participants in each
group, i.e. a total effective sample size of 2 * 144 = 288
participants. Based on the experience with similar pro-
jects completed at the CHCs, the expected attrition rate
is 25%. This implies that almost 400 participants should
be recruited.
Inclusion criteria
The study aims at assessing the effects in routine care,
i.e. for a wide age range and a number of cardiovascu-
lar diagnoses on inclusion criteria. To be eligible to
participate in the AWATAR trial, patients have to meet
following criteria:
– age between 40 and 75 years-old;
– ability to provide informed consent based on
information about perceived health benefits and
risks connected with participation in the study from
the treating cardiologist;
– willingness to accept randomization and
participation in the assessment procedures;
– presence of one or more below listed cardiovascular
diagnosis (Table 2) at the recruitment moment of
participants.
Table 1 SPIRIT schedule of enrolment, interventions and
assessments for experimental and control group in the
AWATAR trial
Study period















PA questionnaire X X
Anthropometry X X
Clinical data X X
Health literacy X X
Lifestyle variables X X
Socio-demographic data X X
Feasibility X X
(X - application of procedure in both experimental and control group; # -
application of EXPERT tool in experimental group or application of standard
informative procedure in control group)
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Exclusion criteria
After the participants’ inclusion, specific exclusion
criteria regard minimization the risk of (sudden)
exercise-induced cardiac events. Exclusion criteria
include the presence of specific CVD problems that
significantly increasing risks of sudden cardiovascular
events, also identified as potential contraindications of
PA on cardiovascular patients. These are summarized
in Table 3-List A regarding specific cardiovascular
conditions and List B regarding non-CVD specific
exclusion.
Randomization and allocation
The AWATAR trial will be realized as a two arm, parallel-
group, randomized controlled trial with an allocation ratio
of 1:1. Participants will be randomly assigned, with equal
probability to fall into each of two trial arms into: the
experimental group (EG) and the 3 months waiting list
control group (CG). For the allocation process, a
computer-generated allocation sequence will be prepared
by an investigator with no involvement in the trial. Alloca-
tion sequence will be stratified by the cardiovascular diag-
nosis of participants and will not be disclosed to the
cardiologists or persons from the investigation team partici-
pating in the trial. This important blinding step will prevent
assignment of patients into EG or CG groups according to
someone’s personal preferences.
For the assignment process, we will prepare identical,
sealed, opaque, stapled envelopes, sequentially numbered
by generated allocation sequence. Each envelope will
contain the written code (EG or CG) indicating experi-
mental or control group. This code containing envelope
will be drawn by one member of investigatory team
(AZ). The nature of the intervention makes it impossible
to ensure blinding of the investigatory team or partici-
pants in presented trial settings.
Intervention
Experimental condition
After baseline assessments, patients in experimental group
(EG) will undergo behavioural counselling. During the 30-
min long consultation EG patients will receive standard,
usual-cardio-care lifestyle, hypertension and cardiovascu-
lar instructions, except recommendations for physical
activities (PA). Instruction s on this PA domain will be
provided exclusively through the digital training and deci-
sion support (EXPERT) tool. They will receive this infor-
mation immediately after the baseline assessments by a
trained member of the investigatory team (AZ).
The EXPERT tool is an interactive digital training and
decision support system for optimized exercise prescrip-
tion in cardiovascular disease patients. The tool was
developed by a working group connecting 33 experts in
the rehabilitation of chronic internal diseases and three
computer science experts from 11 European countries.
During the construction of the system, clinical and
rehabilitation experts reviewed all relevant and access-
ible recommendations, current clinical guidelines, studies
and expert opinions in exercise intervention of cardiovas-
cular patients. Specific exercise intervention goals were
formulated for each different CVD, CVD risk factor and
other chronic non-cardiovascular comorbidity.
The EXPERT tool was designed to provide optimized
exercise prescription based on detailed overview of
patient’s diagnosis, prognostics, complications and medi-
cation. The digital system requires data input in four
Table 2 Inclusion criteria: present cardiovascular diagnosis at
the recruitment moment of participants
Cardiovascular diagnosis
coronary artery disease (both, with or without percutaneous
coronary intervention)
coronary artery bypass graft surgery, or endoscopic traumatic
coronary artery bypass graft surgery




implantable cardioverter defibrillator or pacemaker
ventricular assist devices
heart transplantation
valve disease or surgery
congenital heart disease
non-severe pulmonary hypertension
Table 3 Exclusion criteria: presence of specific cardiovascular
conditions and non-specific exclusion criteria
List A Presence of specific cardiovascular conditions
uncontrollable hypertension
decompensated heart failure




acute myocarditis, endocarditis, or pericarditis
aortic dissection
Marfan syndrome
List B Presence of non-CVD specific exclusion criteria
malignancy (active cancer) or life-threatening disease
bed-bound patient status
participation or plan to participate in other study during
trial execution
plan to move during the trial execution
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steps, the data about patient’s clinical and cardiological
characteristics (parameters), patient’s medication data
and data summarizing patient’s adverse events registered
during exercise testing. The EXPERT tool is able to gen-
erate exercise prescriptions even some of the relevant
parameters are missing. In this case, unavailable data are
not reflected in the prescription process and should
negatively affect individualization and optimization rate
of recommendations for patient in final.
After execution of the required data input, the EX-
PERT tool is ready to generate an exercise prescription
(type of exercise) defining five regulatory parameters:
1) intensity and 2) frequency of the exercise, 3) dur-
ation of each exercise session, 4) duration of the train-
ing program, 5) feasibility of the strength training
during the training program. Additionally, the pre-
scription contains exercise contraindications and safety
precautions for a certain type of exercise. The gener-
ated exercise prescription will be explained and dis-
cussed in details by a member of the investigatory
team and will be printed in two paper copies for the
patient. We will forward the EXPERT tool’s output in
electronic form to patient’s email address. All outputs
will be safely stored for replication or exercise pre-
scription history review.
Control condition
Patients randomized to the (3 months waiting) CG will
after baseline assessment receive standard, usual-cardio-
care lifestyle, hypertension and usual cardiovascular in-
structions, so also in the domain of recommendations for
physical activities. The exercise prescription process during
consultation in the CG will be constructed in accordance
with published ECS guidelines and recommendations for
CVD secondary prevention [54]. The timing and mediator
of behavioural counselling of the CG will be same as on the
EG. Participants in CG will be informed, that after expir-
ation of 3 months control period, and they will be offered
to receive an identical digital-based (EXPERT) exercise pre-
scription as patients in EG. Through the intervention all
participants are instructed to maintain the standard treat-
ment. Patients who declined to participate in the trial and
those who will cancel participation during implementation
of the trial will be asked to complete a short questionnaire
to collect basic socio-demographic and behavioural data
and explore the reasons for non-participation or non-
continuation in the trial.
Procedure
Assessments will be conducted at two time points –
(prior to patient’s behavioural consultation and 3 months
follow-up the consultation). Completion of measure-
ments should take maximally 30 min. One member of
the investigatory team (AZ) will perform all measures in
the trial. A dedicated member will undergo a training ses-
sion to ensure consistency of assessment protocol and
validity and reliability of applied diagnostics instruments.
Primary outcome measures
The primary outcome is exercise recommendations adher-
ence as assessed by agreement between the patients re-
ported and the prescribed indices of exercise. The indices
are type, duration, intensity and frequency of exercise.
Patient-reported type, duration, intensity and frequency of
exercise will be assessed using a short self-report question-
naire (Table 4), reflecting the construction and definition
of exercise prescriptions generated by the EXPERT tool.
The questionnaire will be filled with assistance of an inves-
tigatory team member and he will ask participants to re-
port regularity on exercise over the last year and describe
in detail the type, duration, intensity and frequency of exer-
cise realized over the last 3 months. Exercise recommenda-
tions adherence will be determined as agreement between
indices of exercise prescription delivered by EXPERT tool
and self-reported indices of exercise performed in monitor-
ing period (3 months). In the follow up assessment, the last
section of the questionnaire will be dedicated on the gen-
eral evaluation of PA behavioural change (by the question:
“Have you registered a change in your PA behaviour during
the last three months?”; with options for answer: “Defin-
itely/Partially/Only limited change/Not at all”).
Table 4 Measurement dimensions of exercise
recommendations adherence and outcome variables
Measurement dimensions Outcomes variables (independent data
for last 3 months recall period)
Type of exercise • Endurance training (walking, bicycling,
swimming)
• Strength training (free weight or
resistance strength training, weightlifting)
• Speed training (all short duration exercises
with high intensity)
• Anaerobic training (all exercises generating
“lactate feelings”)










• 121 and more min.
Intensity of exercise
(typical intensity)
• Light Activity: an activity that does not
cause you to ‘huff and puff’.
• Moderate Activity: an activity that makes
you breathe harder than normal, but
only a little.
• Vigorous Activity: an activity that makes




• 3–6 per week
• 1–2 per week
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Secondary outcome measures
Secondary outcomes include anthropometry (body mass
index, weight to height ratio), performance of leisure
time physical activities, parameters of medical comorbid-
ities (classification/severity) and clinical characteristics
of the participants (systolic and diastolic pressure; blood
total and low-density lipoprotein cholesterol concentra-
tion; fasting glycaemia; resting and peak heart rate dur-
ing exercise testing; and peak oxygen uptake capacity).
Anthropometry Body mass index will be calculated
(weight/(height)2) based on body height (m) and weight
(kg) determined by a stadiometer and calibrated electronic
scale, respectively. Waist-to-height ratio will be calculated
by a standard formula (waist circumference/height), based
on body height and waist circumference (cm) measured
using a non-elastic tape measure at the narrowest point
between the last rib and the iliac crest at the end of a
normal expiration.
Leisure time physical activities To measure the preva-
lence of PA unqualified as sport-related or performance-
oriented exercises (gardening, yard work, housework,
carrying for another, home repairs) we will measure leis-
ure time behaviours of participants via International
Physical Activity Questionnaire – Short Form (IPAQ-
SF). The IPAQ-SF is a validated and reliable question-
naire for assessment of frequency (days per week) and
time (minutes per day) of PA realized during a past
7 days recall period in five domains: work, transporta-
tion, garden or yard, home, and leisure time [55]. The
original English IPAQ-SF version was translated and
cross-culturally adapted in several steps according to
methodology established and described by the IPAQ
developers group [http://www.ipaq.ki.se]. The Slovak
IPAQ-SF version was subsequently reviewed by an
expert and pre-tested [56, 57].
Background measures
Clinical data included a list of patient’s CVD, CVD risk
factors, other chronic non-cardiovascular co-morbidities,
patient’s medication, systolic and diastolic blood pressure,
blood total and low-density lipoprotein cholesterol con-
centration, fasting glycaemia, resting, and known patient’s
adverse events registered during exercise testing. These
data will be collected and reported by patient’s cardiologist
and transferred from the patient’s medical record to the
study file.
The Health literacy (HL) level will be assessed using
The Health Literacy Questionnaire (HLQ) [58, 59]. This
questionnaire comprises nine domains to provide a de-
tailed profile of HL of populations, groups or patients of
interest. The HLQ is divided into two parts which differ
in response categories. Part 1 (domains 1–5) has 4 re-
sponse categories rating the extent of agreement from 1
to 4. Part 2 (domains 6–9) has 5 response categories
rating the level of difficulty from cannot do or always
difficult (1), to always easy (5). Each domain was scored
as the average of the item scores. The score ranges from
1 to 4 or 1 to 5 respectively, a higher score indicating
higher level of health literacy. Cronbachs alpha in an
earlier Slovak sample ranged from 0.73 to 0.84 among 9
HLQ domains [59].
Also, lifestyle variables and socio-demographic data
will be collected via questionnaire developed for this
study. The participants will provide standard informa-
tion about age, education completed, marital status,
number and age of descendants, living and work condi-
tions and history, drinking and smoking habits.
Feasibility
Eligibility, compliance, attrition and safety rates will be
registered during the recruitment and implementation of
the study. The principal investigator, in cooperation with
the cardiologists will register eligible patients out of all
patients from the registries. Also, the number of those
willing to participate out of all eligible patients will be
recorded. During the intervention period, compliance
and adherence data as well as the reasons for discontin-
uations will be collected. There are no contraindications,
but specific measures incorporating partial body weight
support may be necessary.
Data analysis
All data analyses will be carried out using statistical soft-
ware package IBM SPSS 22.0 or equivalent. Analyses will
include standard descriptive statistics, Pearson chi-
squared test for categorical variables, independent- and
paired-sample tests of differences for continual variables
(e.g. t-test/U-test, ANOVA) adjusted for baseline values.
The agreement between indices of exercise prescription
delivered by EXPERT tool and self-reported indices of
exercise performed in monitoring periods will be tested
using intra-class correlation test. Modelling of associa-
tions with possible adjustments will be conducted with
regression analysis (linear and/or binary logistic). Ana-
lysis will be performed primarily based on intention-to-
treat. In addition, a per-protocol analysis including only
patients with no missing observations of the variable of
interest will be performed. All tests will be two-tailed
with statistical significance set at an α level of 0,05.
Monitoring
The study will be supervised by a Data Safety and Monitor-
ing Board consisting of one independent, internationally
recognized clinical researcher (Assoc. Prof. Viola Vargova
MD), one representative (cardiologist) from each cooper-
ating Cardiovascular Healthcare Centre as an advisor and
experts in health psychology (PK), exercise psychology
(JP), trial management (PB), and exercise physiology (AZ).
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The Board will be the policy and decision-making author-
ity of the trial. A principal investigator (AB) will be re-
sponsible for the organization of the research activities
and communication with study patients, research co-
operators and partners. Three investigator assistants will
manage the central randomization (PB), project and ethics
reporting (JP) and collection, protection, storing and pro-
cessing of trial data (AZ). All assessments and exercise
prescriptions in trial will be performed by one member of
investigatory team (AZ).
Discussion
In the present AWATAR trial the effectiveness of digital
training and decision support system on patients with
CVD will be investigated for the first time. Meeting PA
recommendations is a challenging public health issue.
Fulfilment of exercise recommendations is a key factor
in CVD prevention [60, 61]. However, adherence rates
among cardiovascular patients are deep below the ex-
pectation rates [39].
The strength of this trial is its study design, ideal for
determining the effectiveness of an intervention in a
real-world setting. In the Methods section, we specified
a wide range of inclusion criteria to recruit the study
population as similar as possible to the population on
which the intervention tool is meant to be used. We
tried to reflect the normal range of diversity in CVD
severity, presence of comorbidities, and medication pro-
files seen in everyday clinical practice. The intervention
(EXPERT) tool is an easy-accessible digital instrument
and the outcomes are comprehensible for a range of
users, including clinicians, patients, policy makers, and
health commissioners. Also, the strong side of this
survey is the use of the questionnaire items designed to
specifically address the characteristics of exercise pre-
scription for patients with CVD. The questionnaire
items were developed by copping the exercise prescrip-
tion variables defined by EXPERT tool.
The application of waiting control group design is weak
side of the presented design. Based on similar studies, we
expect that only one-third of patients randomized on con-
trol group will agree with control group settings and
protocol. The high attrition rate in control group and the
subsequently unbalanced drop-out rate between groups
should affect internal validity of our study.
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